Increased non-relapse mortality due to high-dose cytarabine plus CY/TBI in BMT/PBSCT for acute lymphoblastic leukaemia in adults

Yasuyuki Arai, Tadakazu Kondo, Akio Shigematsu, Junji Tanaka, Kazuteru Ohashi, Takahiro Fukuda, Toshiro Kawakita, Takehiko Mori, Takumi Hoshino, Makoto Onizuka, Yukiyasu Ozawa, Shuro Yoshida, Yasunori Ueda, Ishikazu Mizuno, Yoshiko Atsuta, Shuichi Mizuta

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The efficacy of high-dose cytarabine (HDCA) plus cyclophosphamide/total-body irradiation (CY/TBI) has been proved in cord blood transplantation (CBT) for acute lymphoblastic leukaemia (ALL), but not in bone marrow or peripheral blood stem cell transplantation (BMT/PBSCT). In this cohort study, we compared the prognosis of CY/TBI (N = 1244) and HDCA/CY/TBI (N = 316) regimens in BMT/PBSCT for ALL. The addition of HDCA decreased post-transplant relapse, while significantly increasing non-relapse mortality (risk ratio, 1·33), and overall survival was not improved. The positive effects of HDCA reported in CBT cannot be extrapolated to BMT/PBSCT, and HDCA may not be recommended in these procedures.

Original languageEnglish
JournalBritish Journal of Haematology
DOIs
Publication statusAccepted/In press - 2017

Fingerprint

Whole-Body Irradiation
Cytarabine
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Cyclophosphamide
Mortality
Fetal Blood
Transplantation
Peripheral Blood Stem Cell Transplantation
Cohort Studies
Bone Marrow
Odds Ratio
Transplants
Recurrence

Keywords

  • Acute lymphoblastic leukaemia
  • Allogeneic transplantation
  • BMT/PBSCT
  • Conditioning regimens
  • High-dose cytarabine

ASJC Scopus subject areas

  • Hematology

Cite this

Increased non-relapse mortality due to high-dose cytarabine plus CY/TBI in BMT/PBSCT for acute lymphoblastic leukaemia in adults. / Arai, Yasuyuki; Kondo, Tadakazu; Shigematsu, Akio; Tanaka, Junji; Ohashi, Kazuteru; Fukuda, Takahiro; Kawakita, Toshiro; Mori, Takehiko; Hoshino, Takumi; Onizuka, Makoto; Ozawa, Yukiyasu; Yoshida, Shuro; Ueda, Yasunori; Mizuno, Ishikazu; Atsuta, Yoshiko; Mizuta, Shuichi.

In: British Journal of Haematology, 2017.

Research output: Contribution to journalArticle

Arai, Y, Kondo, T, Shigematsu, A, Tanaka, J, Ohashi, K, Fukuda, T, Kawakita, T, Mori, T, Hoshino, T, Onizuka, M, Ozawa, Y, Yoshida, S, Ueda, Y, Mizuno, I, Atsuta, Y & Mizuta, S 2017, 'Increased non-relapse mortality due to high-dose cytarabine plus CY/TBI in BMT/PBSCT for acute lymphoblastic leukaemia in adults', British Journal of Haematology. https://doi.org/10.1111/bjh.14652
Arai, Yasuyuki ; Kondo, Tadakazu ; Shigematsu, Akio ; Tanaka, Junji ; Ohashi, Kazuteru ; Fukuda, Takahiro ; Kawakita, Toshiro ; Mori, Takehiko ; Hoshino, Takumi ; Onizuka, Makoto ; Ozawa, Yukiyasu ; Yoshida, Shuro ; Ueda, Yasunori ; Mizuno, Ishikazu ; Atsuta, Yoshiko ; Mizuta, Shuichi. / Increased non-relapse mortality due to high-dose cytarabine plus CY/TBI in BMT/PBSCT for acute lymphoblastic leukaemia in adults. In: British Journal of Haematology. 2017.
@article{37f3fddc4b2348f38c8c9e3e7605e181,
title = "Increased non-relapse mortality due to high-dose cytarabine plus CY/TBI in BMT/PBSCT for acute lymphoblastic leukaemia in adults",
abstract = "The efficacy of high-dose cytarabine (HDCA) plus cyclophosphamide/total-body irradiation (CY/TBI) has been proved in cord blood transplantation (CBT) for acute lymphoblastic leukaemia (ALL), but not in bone marrow or peripheral blood stem cell transplantation (BMT/PBSCT). In this cohort study, we compared the prognosis of CY/TBI (N = 1244) and HDCA/CY/TBI (N = 316) regimens in BMT/PBSCT for ALL. The addition of HDCA decreased post-transplant relapse, while significantly increasing non-relapse mortality (risk ratio, 1·33), and overall survival was not improved. The positive effects of HDCA reported in CBT cannot be extrapolated to BMT/PBSCT, and HDCA may not be recommended in these procedures.",
keywords = "Acute lymphoblastic leukaemia, Allogeneic transplantation, BMT/PBSCT, Conditioning regimens, High-dose cytarabine",
author = "Yasuyuki Arai and Tadakazu Kondo and Akio Shigematsu and Junji Tanaka and Kazuteru Ohashi and Takahiro Fukuda and Toshiro Kawakita and Takehiko Mori and Takumi Hoshino and Makoto Onizuka and Yukiyasu Ozawa and Shuro Yoshida and Yasunori Ueda and Ishikazu Mizuno and Yoshiko Atsuta and Shuichi Mizuta",
year = "2017",
doi = "10.1111/bjh.14652",
language = "English",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Increased non-relapse mortality due to high-dose cytarabine plus CY/TBI in BMT/PBSCT for acute lymphoblastic leukaemia in adults

AU - Arai, Yasuyuki

AU - Kondo, Tadakazu

AU - Shigematsu, Akio

AU - Tanaka, Junji

AU - Ohashi, Kazuteru

AU - Fukuda, Takahiro

AU - Kawakita, Toshiro

AU - Mori, Takehiko

AU - Hoshino, Takumi

AU - Onizuka, Makoto

AU - Ozawa, Yukiyasu

AU - Yoshida, Shuro

AU - Ueda, Yasunori

AU - Mizuno, Ishikazu

AU - Atsuta, Yoshiko

AU - Mizuta, Shuichi

PY - 2017

Y1 - 2017

N2 - The efficacy of high-dose cytarabine (HDCA) plus cyclophosphamide/total-body irradiation (CY/TBI) has been proved in cord blood transplantation (CBT) for acute lymphoblastic leukaemia (ALL), but not in bone marrow or peripheral blood stem cell transplantation (BMT/PBSCT). In this cohort study, we compared the prognosis of CY/TBI (N = 1244) and HDCA/CY/TBI (N = 316) regimens in BMT/PBSCT for ALL. The addition of HDCA decreased post-transplant relapse, while significantly increasing non-relapse mortality (risk ratio, 1·33), and overall survival was not improved. The positive effects of HDCA reported in CBT cannot be extrapolated to BMT/PBSCT, and HDCA may not be recommended in these procedures.

AB - The efficacy of high-dose cytarabine (HDCA) plus cyclophosphamide/total-body irradiation (CY/TBI) has been proved in cord blood transplantation (CBT) for acute lymphoblastic leukaemia (ALL), but not in bone marrow or peripheral blood stem cell transplantation (BMT/PBSCT). In this cohort study, we compared the prognosis of CY/TBI (N = 1244) and HDCA/CY/TBI (N = 316) regimens in BMT/PBSCT for ALL. The addition of HDCA decreased post-transplant relapse, while significantly increasing non-relapse mortality (risk ratio, 1·33), and overall survival was not improved. The positive effects of HDCA reported in CBT cannot be extrapolated to BMT/PBSCT, and HDCA may not be recommended in these procedures.

KW - Acute lymphoblastic leukaemia

KW - Allogeneic transplantation

KW - BMT/PBSCT

KW - Conditioning regimens

KW - High-dose cytarabine

UR - http://www.scopus.com/inward/record.url?scp=85018760119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018760119&partnerID=8YFLogxK

U2 - 10.1111/bjh.14652

DO - 10.1111/bjh.14652

M3 - Article

C2 - 28439877

AN - SCOPUS:85018760119

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

ER -